Search
Powered By HealthLine
Health Tools
 Allergy Questions and Answers
 Allergic Reaction Guide
 Seasonal Allergies Guide
 Is it a Cold or Allergies?
 Food Allergy Guide
Featured Conditions
 Allergy
 Asthma
 Diet & Exercise
 Sleep
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
Drug DescriptionSide Effects & Drug InteractionsWarnings & PrecautionsAdditional Info
Clinical PharmacologyOverdosage & ContraindicationsIndications & DosagePatient Info

Ortho Tri-Cyclen

[Noregestimate/Ethinyl Estradiol]


Text Continues Below



Overdosage & Contraindications
CONTRAINDICATIONS

Oral contraceptives should not be used in women who currently have the following conditions:

° Thrombophlebitis or thromboembolic disorders
° A past history of deep vein thrombophlebitis or thromboembolic disorders ° Cerebral vascular or coronary artery disease
° Migraine with focal aura
° Known or suspected carcinoma of the breast
° Carcinoma of the endometrium or other known or suspected estrogendependent neoplasia
° Undiagnosed abnormal genital bleeding
° Cholestatic jaundice of pregnancy or jaundice with prior pill use
° Acute or chronic hepatocellular disease with abnormal liver function
° Hepatic adenomas or carcinomas
° Known or suspected pregnancy ° Hypersensitivity to any component of this product

OVERDOSAGE

Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding may occur in females.









HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2013. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire